Valeo Pharma (TSE:VPH) has released an update.
Valeo Pharma Inc. has revised its credit agreement with Sagard Healthcare Royalty Partners, extending the due date for an initial $10 million payment and reducing its loan principal by approximately C$6.5 million. The amendment offers Valeo Pharma enhanced financial flexibility to pursue its strategic plans. The company focuses on the commercialization of specialty pharmaceuticals in Canada.
For further insights into TSE:VPH stock, check out TipRanks’ Stock Analysis page.
